Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Guopan Yu, Zurong Yao, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Ziwen Guo, Zhiqiang Sun, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Qifa Liu

Blood (2024) 144 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2024-206872

Published: 2024

Journal Articles

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Guopan Yu, Yishan Chen, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Xin Du, Danian Nie, Ziwen Guo, Zhiqiang Sun, Hongyu Zhang, Dongjun Lin, Xinquan Liang, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Baohong Ping, Qifa Liu

Blood (2024) 144 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2024-201974

Published: 2024

Journal Articles

Photoablation with the Aurolase System Reduces T Cell Exhaustion and Synergizes with Immunotherapies in Lymphoma

Adam Yuh Lin, Eva Yang, Jonathan S Rink, Dan Xu, Stephen Miller, Leo I. Gordon

Blood (2023) 142 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2023-185400

Published: 2023

Journal Articles

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Guopan Yu, Zhao Yin, Zurong Yao, Xiaqi Nie, Hua Jin, Yu Zhang, Dan Xu, Xuejie Jiang, Baohong Ping

Blood (2023) 142 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2023-182668

Published: 2023

Journal Articles

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Yu Zhang, Xuejie Jiang, Xiaqi Nie, Zurong Yao, Dan Xu, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2023-184772

Published: 2023

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Hui Yang, Xiaoyu Chen, Yuemin Gong, Yawen Zhang, Jinge Xu, Dan Xu, Jianyong Li, Guangsheng He

Blood (2023) 142 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2023-189210

Published: 2023

Journal Articles

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Qixin Sun, Zhengqian Huang, Yu Zhang, Guopan Yu

Blood (2022) 140 (Supplement 1): 9097.

https://doi.org/10.1182/blood-2022-159589

Published: 2022

Journal Articles

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Guopan Yu, Zhao Yin, Dan Xu, Xuejie Jiang, Jieyu Ye, Yu Zhang

Blood (2022) 140 (Supplement 1): 11740.

https://doi.org/10.1182/blood-2022-169333

Published: 2022

Journal Articles

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Liu Hui, MD, Li Xuan, MD, Ren Lin, MD, Lan Deng, MD PhD, Fen Huang, MD, Zhiping Fan, MD, Danian Nie, MD, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, MD, Jieyu Ye, MD PhD, Hua Jin, Dongjun Lin, MD, Liping MA, MD, Jing Sun, MD, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 3303.

https://doi.org/10.1182/blood-2019-126901

Published: 2019

Journal Articles

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Guopan Yu, Jiaheng Zhou, Jinchan Zhou, Jiale Qiu, Zhao Yin, Changxin Yin, Dan Xu, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2018-99-116558

Published: 2018

Journal Articles

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Xuejie Jiang, MD, Changxin Yin, Junya Sun, Jiaying Cheng, Qiang Wang, Guopan Yu, Ling Jiang, Dan Xu, Xiaoli Liu, Ru Feng, MD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2018-99-111063

Published: 2018

Journal Articles

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Guopan Yu, Changxin Yin, Fuqun Wu, Ling Jiang, Zhongxin Zheng, Dan Xu, Jiaheng Zhou, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5249.

https://doi.org/10.1182/blood-2018-99-113494

Published: 2018

Journal Articles

Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

Guo-Pan Yu, MD, Fang Chen, Dan Xu, Changxin Yin, Qifa Liu, Jing Sun, MD, Zhiping Fan, Qiang Wang, PhD, Liu Xiaoli, MD, Qianli Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 4522.

https://doi.org/10.1182/blood.V130.Suppl_1.4522.4522

Published: 2017

Journal Articles

A New Multi-Factor Risk Score System Depending on Gene Mutation and Overexpression for Predicting the Outcome in AML1-ETO-Positive Acute Myeloid Leukemia

Guo-Pan Yu, MD, Changxin Yin, Fuqun Wu, Dan Xu, Zhongxin Zheng, Ling Jiang, PhD MD, Fang Chen, Xuejie Jiang, MD, Qifa Liu, Fanyi Meng

Blood (2017) 130 (Supplement 1): 5088.

https://doi.org/10.1182/blood.V130.Suppl_1.5088.5088

Published: 2017

Journal Articles

Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia

Xuejie Jiang, MD, Fang Chen, Changxin Yin, Ling Jiang, PhD MD, Guo-Pan Yu, MD, Dan Xu, Jing Sun, MD, Xiaoli Liu, MD PhD, Qifa Liu

Blood (2017) 130 (Supplement 1): 5089.

https://doi.org/10.1182/blood.V130.Suppl_1.5089.5089

Published: 2017

Journal Articles

BM-MSC Hhip Induced Microenvironment Protection from Chemotherapy in AML Via Ptch/Smo/Gli Pathwa

Xuejie Jiang, Dan Xu, Fang Chen, Ling Jiang, Guopan Yu, Fanyi Meng, Xiaoli Liu, PhD, Qifa Liu, MD

Blood (2016) 128 (22): 5235.

https://doi.org/10.1182/blood.V128.22.5235.5235

Published: 2016

Journal Articles

Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia

Guopan Yu, Dan Xu, Qifa Liu, MD, Jing Sun, MD, Zhiping Fan, Qiang Wang, Xiaoli Liu, Qianli Jiang, MD PhD

Blood (2015) 126 (23): 1302.

https://doi.org/10.1182/blood.V126.23.1302.1302

Published: 2015

Journal Articles

The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients

Xuejie Jiang, Zhixiang Wang, Changxin Yin, Guopan Yu, Jieyu Ye, Yu Zhang, Zhiping Fan, Dan Xu, Xiaoli Liu, Ru Feng, Bing Xu, PhD, Jing Sun, MD, Qifa Liu, Bing Z Carter, Fanyi Meng

Blood (2015) 126 (23): 4932.

https://doi.org/10.1182/blood.V126.23.4932.4932

Published: 2015

NARROW

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Photoablation with the Aurolase System Reduces T Cell Exhaustion and Synergizes with Immunotherapies in Lymphoma

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

No Benefits from Glucocorticoid Maintenance Therapy in Patients with PNH

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

A New Multi-Factor Risk Score System Depending on Gene Mutation and Overexpression for Predicting the Outcome in AML1-ETO-Positive Acute Myeloid Leukemia

Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia

BM-MSC Hhip Induced Microenvironment Protection from Chemotherapy in AML Via Ptch/Smo/Gli Pathwa

Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia

The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only